Z-IL-CHO (GSI-XII) can reduce the mRNA content of HES1 in TMD8 cell lines established from DLBCL patients, proving its potential therapeutic effect in DLBCL [291]. Here, HES1 is linked to diffuse large B-cell lymphoma.